BioInformant

Your Global Leader in Stem Cell Market Research

You are here: Home / Archives for Stem Cells / iPS Cells

Stem Cell Treatment for Parkinson’s Disease

By

At least eight clinical trials worldwide and one physician-led study in Japan are exploring stem cells as a treatment approach to Parkinson’s disease. This research progress is critical, because the disease debilitates the body and causes tremors and numbness, loss of motor function, and stooping. Eventually, left untreated, Parkinson’s disease leads to death. The good news is, researchers are showing significant results in their studies on the link between stem cells and Parkinson’s disease.

In this article:

  1. An Introduction to Stem Cells
  2. What Are Stem Cells?
  3. What Is Parkinson’s Disease?
  4. How Does Stem Cell Therapy Work?
  5. How Can Stem Cells Help Heal This Condition?
  6. Clinical Study in Japan for Parkinson’s Disease
  7. Are We Close to a Widespread Solution?

[Read more…]

Fate Therapeutics Announces FDA Clearance of Landmark IND for FT500 iPSC-derived, Off-the-Shelf NK Cell Cancer Immunotherapy

By

Company to Initiate First-ever U.S. Clinical Investigation of iPSC-derived Cell Product

FT500 to be Featured in Oral Presentation on Monday, December 3 at ASH Annual Meeting

SAN DIEGO, Nov. 30, 2018  — Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that the U.S. Food and Drug Administration (FDA) has allowed its Investigational New Drug (IND) Application for FT500, the Company’s universal, off-the-shelf natural killer (NK) cell product candidate derived from a clonal master induced pluripotent stem cell (iPSC) line. [Read more…]

Evotec to Pair Its iPSC Platform for Drug Discovery with Immuneering’s AI Technology

By

Induced pluripotent stem cells are a type of pluripotent stem cell that can be created from differentiated (“adult”) cells. iPSCs are increasingly being explored for applications within drug development and discovery. This is because patient-derived somatic cells (for example, fibroblasts) can be reprogrammed to produce iPSCs that have disease-specific genetic aberrations. These cells can then be differentiated into the disease-affected cell type (for example, neurons in neurodegenerative diseases). [Read more…]

SERAXIS Inc. publishes clinical trial considerations for a type 1 diabetes stem cell-derived therapy

By

SeraxisGERMANTOWN, Md., Nov. 12, 2018 — SERAXIS Inc., a rapidly growing regenerative medicine company today announced the publication of important trial considerations for SR-01, its pluripotent stem cell-derived islet therapy for insulin-dependent diabetes.

An analysis of islet transplant trials registered on clinicaltrials.gov was conducted with the goal of extracting insights to apply in the study design of SERAXIS lead candidate, SR-01 for the treatment of type 1 diabetes. The results of this analysis were published this week in Stem Cells Translational Medicine (doi:10.1002/sctm.18-0156). SR-01 is a combination therapy of insulin-producing cells encapsulated in the retrievable biocompatible SeraGraftTM device, designed to prevent immune system access to the cells after implantation. [Read more…]

iPS Cell Market Poised for Burgeoning Growth

By

Recent years have seen major advances in the clinical applications of iPSCs, with Cynata Therapeutics progressing the world’s first formal trial of an iPSC-derived cell therapeutic and demonstrating that CYP-001, its lead iPSC-derived mesenchymal stem cell (MSC) product candidate, met all safety and efficacy endpoints in its Phase 1 trial for GvHD.

With multiple physician-led iPSC studies also underway in Japan for applications ranging from Parkinson’s disease to heart disease, the iPSC market is poised to for burgeoning growth. There has also been dramatic progress with production and differentiation technologies related to iPSCs, as well as growing use of iPSCs within drug discovery, disease modelling, tissue engineering, and precision medicine. [Read more…]

BioInformant's World-Class Clients